Your browser doesn't support javascript.
loading
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti, F; Gugliotta, G; Breccia, M; Stagno, F; Iurlo, A; Albano, F; Abruzzese, E; Martino, B; Levato, L; Intermesoli, T; Pregno, P; Rossi, G; Gherlinzoni, F; Leoni, P; Cavazzini, F; Venturi, C; Soverini, S; Testoni, N; Alimena, G; Cavo, M; Martinelli, G; Pane, F; Saglio, G; Rosti, G; Baccarani, M.
Afiliación
  • Castagnetti F; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L and A Seràgnoli', University of Bologna, 'S Orsola-Malpighi' University Hospital, Bologna, Italy.
  • Gugliotta G; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L and A Seràgnoli', University of Bologna, 'S Orsola-Malpighi' University Hospital, Bologna, Italy.
  • Breccia M; Chair of Hematology, 'La Sapienza' University, Roma, Italy.
  • Stagno F; Chair of Hematology, University of Catania, Catania, Italy.
  • Iurlo A; Oncohematology of the Elderly Unit, Oncohematology Division, IRCCS Ca' Granda - Maggiore University Hospital, Milano, Italy.
  • Albano F; Chair of Hematology, University of Bari, Bari, Italy.
  • Abruzzese E; Hematology Unit, 'S Eugenio' Hospital, Roma, Italy.
  • Martino B; Hematology Unit, Azienda Ospedaliera 'Bianchi-Melacrino-Morelli', Reggio Calabria, Italy.
  • Levato L; Hematology Unit, 'Pugliese-Ciaccio' Hospital, Catanzaro, Italy.
  • Intermesoli T; Hematology Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
  • Pregno P; Hematology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.
  • Rossi G; Hematology Unit, Azienda Ospedaliera 'Spedali Civili', Brescia, Italy.
  • Gherlinzoni F; Hematology Unit, 'Ca' Foncello' Hospital, Treviso, Italy.
  • Leoni P; Chair of Hematology, Torrette University Hospital, Ancona, Italy.
  • Cavazzini F; Chair of Hematology, Azienda Ospedaliero Universitaria Arcispedale S Anna, University of Ferrara, Ferrara, Italy.
  • Venturi C; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L and A Seràgnoli', University of Bologna, 'S Orsola-Malpighi' University Hospital, Bologna, Italy.
  • Soverini S; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L and A Seràgnoli', University of Bologna, 'S Orsola-Malpighi' University Hospital, Bologna, Italy.
  • Testoni N; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L and A Seràgnoli', University of Bologna, 'S Orsola-Malpighi' University Hospital, Bologna, Italy.
  • Alimena G; Chair of Hematology, 'La Sapienza' University, Roma, Italy.
  • Cavo M; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L and A Seràgnoli', University of Bologna, 'S Orsola-Malpighi' University Hospital, Bologna, Italy.
  • Martinelli G; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L and A Seràgnoli', University of Bologna, 'S Orsola-Malpighi' University Hospital, Bologna, Italy.
  • Pane F; Department of Biochemistry and Medical Biotechnologies, 'Federico II' University, Napoli, Italy.
  • Saglio G; Chair of Hematology, Department of Clinical and Biological Sciences, 'S Luigi Gonzaga' University Hospital, University of Torino, Orbassano (TO), Italy.
  • Rosti G; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L and A Seràgnoli', University of Bologna, 'S Orsola-Malpighi' University Hospital, Bologna, Italy.
  • Baccarani M; Department of Hematology and Oncology 'L and A Seràgnoli', University of Bologna, Bologna, Italy.
Leukemia ; 29(9): 1823-31, 2015 Sep.
Article en En | MEDLINE | ID: mdl-26088952
For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido